Aprotinin does not prolong the Sonoclot aprotinin-insensitive activated clotting time

Yue Dong, Gregory A. Nuttall, William C. Oliver, Shvetank Agarwal, Mark H. Ereth

Research output: Contribution to journalArticlepeer-review


Study Objective: To determine whether a new Sonoclot-based, aprotinin-insensitive activated clotting time (aiACT) assay yields stable results over a broad range of aprotinin concentrations. Design: Prospective trial conducted on in vitro blood samples. Setting: Tertiary-care teaching medical center. Participants: 19 healthy adult volunteers. Interventions: Whole blood samples were collected from volunteers. Heparin (2 U/mL) and escalating concentrations of aprotinin of 160 to 500 kallikrein inhibitory units (KIU)/mL were added in vitro. Measurements and Main Results: Celite ACT, kaolin ACT, and aiACT assays were completed. The aiACT showed stable activated clotting time (ACT) results on heparinized, noncitrated blood with added aprotinin (P = nonsignificant). In contrast, celite ACT and kaolin ACT were greatly prolonged when aprotinin was added to heparinized, noncitrated, and citrated blood (P < 0.05). The aiACT had consistent results at all aprotinin concentrations (P = nonsignificant). Conclusions: Aprotinin (160, 320, and 500 KIU/mL) significantly prolongs the ACT value with celite and kaolin activators but not with the aprotinin-insensitive activator.

Original languageEnglish (US)
Pages (from-to)424-428
Number of pages5
JournalJournal of Clinical Anesthesia
Issue number6
StatePublished - Sep 2007
Externally publishedYes


  • Activated clotting time
  • Anticoagulation
  • Aprotinin
  • Aprotinin-insensitive ACT
  • Cardiopulmonary bypass
  • Sonoclot analysis

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine


Dive into the research topics of 'Aprotinin does not prolong the Sonoclot aprotinin-insensitive activated clotting time'. Together they form a unique fingerprint.

Cite this